Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice  by Schepers, Abbey et al.
Short-term dexamethasone treatment inhibits vein
graft thickening in hypercholesterolemic
ApoE3Leiden transgenic mice
Abbey Schepers, MD,a,b Nuno M. M. Pires, MSc,a,c Daniel Eefting, MD,a,b Margreet R. de Vries, BSc,a
J. Hajo van Bockel, MD, PhD,b and Paul H. A. Quax, PhD,a,b Leiden, The Netherlands
Objective: The aim of this study was to assess whether the anti-inflammatory agent dexamethasone can inhibit vein graft
thickening without the occurrence of serious side effects.
Methods: Venous interposition grafting was performed in the common carotid artery of hypercholesterolemic
ApoE3Leiden transgenic mice. Mice were treated with dexamethasone (0.15 mg · kg1 · d1 orally), and after 28 days,
vein graft thickening was quantified.
Results: Treatment with dexamethasone resulted in a significant 43% reduction in lesion area without changes in lesion
composition when compared with nontreated controls. However, dexamethasone, when administered for a prolonged
period of time, is known for its potentially serious side effects. To overcome these potential side effects of prolonged
dexamethasone treatment, the effect of a short-term 7-day dexamethasone treatment was studied. This short dexameth-
asone treatment resulted in a 49% decrease of vein graft thickening at 28 days. Furthermore, it was demonstrated that
dexamethasone treatment led to reduced local expression of several proinflammatory cytokines and factors in the vein
grafts 24 hours after surgery. Finally, observations in mice were verified in human saphenous organ cultures. Exposure
to dexamethasone for either 7 or 28 days significantly reduced intimal hyperplasia formation on cultured saphenous vein
segments.
Conclusions: Short-term anti-inflammatory treatment with dexamethasone leads to a significant reduction in vein graft
thickening over an extended period, possibly by the reduction of early expression of proinflammatory cytokines. This
7-day treatment minimizes the risk of unwanted side effects of long-term dexamethasone treatment and may be a new
approach to prevent graft failure. ( J Vasc Surg 2006;43:809-15.)
Clinical Relevance: Aortocoronary and peripheral vein grafts are known to have high failure rates (10%-40% after 1 year
and 50%-60% after 10 years). As a consequence, relapse of ischemic symptoms may occur and may necessitate redo bypass
surgery or (more severely) amputation. Late vein graft failure occurs as a result of the development of intimal hyperplasia
and accelerated atherosclerosis, which lead to vein graft stenosis. In this study, the authors investigated the effect of
short-term dexamethasone treatment on intimal hyperplasia and accelerated atherosclerosis to prevent vein graft failure.Venous bypass grafting is the most common treatment
to bypass an atherosclerotic obstruction of an artery. After
grafting, a remodeling process is initiated in these veins as a
consequence of the increased blood pressure and shear
stress, but also by vessel injury due to surgery. This process
results in the formation of intimal hyperplasia (IH) and
accelerated atherosclerosis, which may lead to obstruction
of the graft. This process is also known as vein graft
disease.1,2 Vein graft disease is the major cause of late graft
failure, with failure rates of 10% to 40% after 1 year and 50%
to 60% after 10 years.3
It has been well established that other forms of vascular
remodeling—for instance, atherosclerosis and postangio-
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processes.4 However, the role of inflammation in vein graft
disease is largely unknown. Morphologic analysis shows
that IH in a vein graft consists mainly of smooth muscle
cells (SMCs), macrophages, and other inflammatory cells,
such as T cells. The important role of inflammatory medi-
ators in both restenosis and atherosclerosis and the pres-
ence of inflammatory cells in vein grafts argue for a role of
inflammation in vein graft disease.
Dexamethasone is known for its anti-inflammatory and
antiproliferative properties and is frequently used for the
experimental treatment of atherosclerosis and restenosis.5-9
Recently, clinical trials have been initiated to investigate the
effect of dexamethasone in in-stent restenosis.10-13
Concerning vein graft disease, the effect of dexameth-
asone treatment on vein graft thickening of the vein graft is
largely unknown and to our knowledge has been studied
only once.14 In this article, the effects of dexamethasone on
vein graft thickening are described. Because long-term
dexamethasone treatment is accompanied by serious side
effects (eg, skin dystrophy, muscle atrophy, and impaired
stress response) and because of its aggravating effect on
spontaneous atherosclerosis development, we studied
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could be as efficient as continuous treatment in preventing
vein graft thickening in a murine model for vein graft
disease. To validate the clinical relevance of the murine
data, experiments were repeated in clinically relevant tissue:
human saphenous vein organ cultures. In these organ cul-
tures, the effect of both 7 and 28 days of exposure to
dexamethasone on IH formation was assessed.
MATERIALS AND METHODS
Mice. All animal experiments were approved by the
TNO animal welfare committee. For all experiments, male
ApoE3Leiden15 mice on a C57/BL6 background, aged
between 14 and 20 weeks, were used. Animals were fed a
cholesterol-enriched high-fat diet (1% cholesterol and
0.05% cholate; Arie Blok, Worden, The Netherlands) start-
ing 3 weeks before the beginning of each experiment. All
mice received water and food ad libitum. Serum cholesterol
levels were determined 1 week before the start of the
experiment and at death. Before surgery, mice were anes-
thetized with midazolam (5 mg/kg; Roche, Basel, Switzer-
land), medetomidine (0.5 mg/kg; Orion, Helsinki, Fin-
land), and fentanyl (0.05 mg/kg; Janssen, Geel, Belgium).
Dexamethasone treatment. For all experiments, mice
were randomly divided into two groups. One group re-
ceived approximately 0.15 mg · kg1 · d1 dexamethasone
dissolved in the drinking water (based on a daily water
intake of 3 mL per mouse) throughout the entire experi-
ment, starting 1 day before the start of each experiment.
Carotid vein graft model. Mice either were treated
with dexamethasone or received no treatment and served as
controls (n 6 in both groups). A venous interposition in
the carotid artery was placed in each mouse as described
previously.16 In brief, the right common carotid artery of
the recipient was dissected free from its surroundings
from the bifurcation at the distal end toward the proximal
end. The artery was cut in the middle and ligated with an
8-0 silk ligature. The caval veins were harvested from
genetically identical donor mice and grafted between the
two ends of the carotid artery by sleeving the ends of the
vein over the artery cuff and ligating them together with an
8-0 silk ligature. At death, animals were perfused in vivo
with 4% formaldehyde for 5 minutes. Vein grafts were
harvested and fixed overnight in 4% formaldehyde, dehy-
drated, and embedded in paraffin.
Quantification of vein graft thickening and
immunohistochemistry. Twenty-eight days after sur-
gery, mice were killed as described previously, and vein
grafts were harvested and embedded in paraffin. Serial cross
sections of the embedded vein graft were made through the
entire specimen and routinely stained with hematoxylin-
phloxin-saffron (HPS). By using serial cross sections for the
analysis, overestimation or underestimation of a treatment
effect due to a non–equally distributed occurrence of vein
graft thickening (as we see both in human vein grafts and in
our murine vein graft interpositions) is prevented.
Measurement of vein graft thickening in the samples
was performed by using image-analysis software (Qwin;Leica, Wetzlarr, Germany). Because only very few layers of
cells are in the media of murine veins and because there is
no morphologic border between the neointima and media,
vein graft thickening, ie, the region between the lumen and
adventitia, was used to define the lesion area. For each
mouse, five equally spaced perpendicular cross sections
were used to determine the vessel wall thickening.
All immunohistochemistry was performed on paraffin-
embedded sections of vein grafts 28 days after surgery. The
cellular composition of the thickened vein grafts was
visualized by using antibodies against macrophages
(AIA31240; Accurate Chemical, Wesbury, USA), T cells
(CD3; Serotec, Oxford, UK), and vascular SMCs
(-smooth muscle actin; Amersham, Buckinghamshire,
UK). The number of SMCs and macrophages was quanti-
fied by computer-assisted morphometric analysis (Qwin)
and expressed as the percentage of total smooth muscle
actin–positive or AIA-positive areas in cross sections. The
T-cell number was determined by counting CD3-positive
cells in the vessel wall of six equally spaced cross sections per
vein graft and divided by the vessel wall surface in these
cross sections.
Prolonged dexamethasone exposure and analysis of
general well-being and atherosclerosis. Side effects of
prolonged dexamethasone treatment, including spontane-
ous atherosclerosis, were studied in mice (n  15) that
received dexamethasone 0.15 mg · kg1 · d1 for 25 weeks.
A group of littermates (n  15) not exposed to dexameth-
asone served as controls. Mice were extensively observed
with regard to daily activity, fur quality, and infections. All
mice were killed after 25 weeks as described previously. The
aortic root and the heart were collected for histologic
analysis, because these locations were previously identified
as atherosclerotic-prone regions.17
The hearts were dissected, stored overnight in phosphate-
buffered 3.8% formalin fixation, and embedded in paraffin.
Serial cross sections (5 m thick) throughout the entire
aortic valve area were used for histologic analysis. Sections
were routinely stained with HPS. Per mouse, four sections
with 30-m intervals were used for quantification of the
atherosclerotic lesion area. The lesion area was determined
by using morphometric software (Qwin).
Human saphenous vein organ culture. Segments of
saphenous veins obtained from patients undergoing saphe-
nous vein stripping (provided by Dr H. Stigter, Deaconess
Hospital, Leiden, The Netherlands) were used for these
cultures. Healthy-looking segments of the stripped veins
were put into culture as previously described.18,19 Seg-
ments (n  4 per group) were exposed to dexamethasone
(0.75 mg/mL of medium) for either 7 or 28 days or served
as controls. After 28 days, segments were harvested, fixed
overnight in formaldehyde (4%), and embedded in paraffin.
All segments were routinely stained by HPS, and the neo-
intimal surface was assessed on multiple sections (n 9 per
vein segment) and quantified with Qwin image-analysis
software.
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thesis, and real-time reverse transcriptase-polymerase
chain reaction. To obtain vein grafts for messenger RNA
(mRNA) isolation, mice (n  4 per group) were either
treated with dexamethasone or received no treatment and
were killed 1 day after vein graft surgery. At death, mice
were perfused with NaCl 0.9%, after which the vein grafts
were harvested and snap-frozen. Total RNA was isolated by
using the RNeasy Mini Kit for fibrous tissue (Qiagen,
Venlor, The Netherlands), and DNA contamination was
excluded with an on-column deoxyribonuclease treatment
(Qiagen). Synthesis of complementary DNA was per-
formed by using 250 ng of mRNA and Ready-To-Go
Beads (Amersham Bs) according to the manufacturer’s
protocol.
Intron-spanning primer-probe sets were designed by
using Primer Express 1.5 software (Applied Biosystems,
Foster City, USA) for monocyte chemotactic protein
(MCP)-1, macrophage inflammatory protein (MIP)-1,
tumor necrosis factor (TNF)-, CD14, and toll-like recep-
tor (TLR)-4 (for sequences, see Table). Glyceraldehyde-3-
phosphate dehydrogenase was used as a housekeeping
gene. The polymerase chain reaction was performed by
using qPCR Mastermix (Eurogentec, Seraing, Belgium).
Analysis of mRNA expression by real-time reverse tran-
scriptase-polymerase chain reaction was performed on an
ABI Prism 7700 sequence detection system (Perkin-Elmer
Biosystems, Boston, USA).
For analysis, the cycle threshold of the gene of inter-
est was subtracted from the cycle threshold of the house-
keeping gene glyceraldehyde-3-phosphate dehydroge-
nase (Ct). Ct was determined as the difference
between the Ct values of the dexamethasone-treated vein
grafts and the normalized Ct value of vein grafts in the
control group (which was the average of Ct values in the
control group). Data are presented as relative expression of
all genes in the dexamethasone-treated group, calculated as
1/(2Ct). In this presentation, the mRNA expression of
Table. Taqman primers and probes for real-time
quantitative RT-PCR
MIP-1 S: 5=-CATGACACTCTGCAACCAAGTCTT-3=
A: 5=-TCCGGCTGTAGGAGAAGCA-3=
P: 5=-CCATATGGAGCTGACACCCCGACTG-3=
MCP-1 S: 5=-GCTGGAGAGCTAACAAGAG-3=
A: 5=-TCTCTTGAGCTTGGTGACA-3=
P: 5=-TACAGCTTCTTTGGGACAC-3=
TNF- S: 5=-CATCTTCTCAAAATTCGAGTGACAA-3=
A: 5=-TGGGAGTAGACAAGGTACAACCC-3=
P: 5=-CACGTCGTAGCAAACCACCAAGTGGA-3=
TLR-4 S: 5=-CATGGAACACATGGCTGCTAA-3=
A: 5=-GTAATTCATACCCCTGGAAAGGAA-3=
P: 5=-CCTTCTGCCCGGTAAGGTCCATGC-
TATAG-3=
CD14 S: 5=-CAGCCCTCTGTCCCCTCAA-3=
A: 5=-TCCATCCCCGCGTTACG-3=
P: 5=-TTCCCGACCCTCCAAGTTTTAGCGC-3=
A, antisense; P, probe; S, sense.all genes in the control group was defined as 1.Statistical analysis. Before the start of each experi-
ment, a power analysis was made to obtain a statistically
sound study. Data are presented as mean SEM. Compar-
isons of morphometric data of murine vein grafts and
reverse transcriptase-polymerase chain reaction data were
performed with the Mann-Whitney rank sum test. Mor-
phometric data of IH in human saphenous veins were
compared by using a paired Student t test. P values .05
were considered statistically significant.
RESULTS
Continuous dexamethasone treatment inhibits vein
graft thickening in a murine vein graft model. The
effect of dexamethasone on vein graft thickening was stud-
ied in ApoE3Leiden mice. Six mice received dexametha-
sone (0.15 mg · kg1 · d1) during the complete experi-
mental period, starting 1 day before surgery, and six mice
served as controls. Mice were killed after 28 days. Preoper-
ative plasma cholesterol levels did not differ between the
dexamethasone and control groups. However, a modest,
yet not significant, increase in plasma cholesterol was seen
in the dexamethasone-treated group at the time of death
(dexamethasone: before surgery, 13.8  1.26 mmol/L; at
death, 15.4 1.28 mmol/L; control: before surgery, 12.7
 1.08 mmol/L; at death, 12.7  3.2 mmol/L). During
the experiment, four of six mice receiving dexamethasone
treatment did not gain weight, compared with one out of
six in the control group. In the dexamethasone-treated
group, thrombosis occurred in one vein graft, and this vein
graft was excluded from analysis.
Quantification of vein graft thickening showed a 43%
reduction in the dexamethasone-treated group compared
with the control group (0.32  0.04 mm2 vs 0.56  0.12
mm2; P  .028; Fig 1, A and B). The luminal area did not
differ between groups (dexamethasone, 0.78  0.1 mm2;
control, 0.75  0.08 mm2; P  .75). The cellular compo-
sition of the thickened graft was not significantly different
between groups, as analyzed by immunohistochemistry.
The thickened vein grafts were mainly composed of SMCs
and macrophages. Furthermore, small numbers of T cells
were present in the vessel wall. The AIA-positive area, re-
flecting macrophages, was 20.8%3.5% in the control group,
compared with 22.7%  3.3% in the dexamethasone-treated
group (Fig 1, D). The -smooth muscle actin–positive area,
reflecting vascular SMCs, was 39.3%  7.2% in the control
group as compared with 40.6% 4.2% in the treated group
(Fig 1, C). Also, the number of T cells did not differ
significantly between groups (control, 6.20 0.68 cells per
square millimeter; dexamethasone, 5.79  1.77 cells per
square millimeter).
Prolonged dexamethasone treatment is accompa-
nied by clinical side effects and increased spontaneous
atherosclerosis in mice. To study whether the slight in-
crease in serum cholesterol and failure to gain weight in the
dexamethasone-treated animals could be addressed as the
start of adverse effects of dexamethasone, we next evaluated
the effect of long-term exposure to dexamethasone in mice.
smooth muscle cells. E, AIA31240 staining representing macro-
phages. n.s., Not significant; dexa, dexamethasone.
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enriched diet were randomly divided into two groups. One
group (n15) was treated for 25 weeks with dexamethasone.
During the course of this 25-week period, animals in the
dexamethasone-treated group progressively showed several
side effects of the use of dexamethasone. Four mice revealed
signs of infection and were terminated. Animals treated with
dexamethasone gained less weight, leading to differences in
body weight at the time of death (25.3  1.9 g vs 30.6 
2.8 g; P  .001). Serum cholesterol levels increased signifi-
cantly in the dexamethasone-treated animals (33.7  7.4
mmol/L) compared with the control group (15.0  3.3
mmol/L; P  .001). Furthermore, dexamethasone-treated
animals expressed reduced daily activity and had impaired fur
quality. Moreover, dexamethasone treatment resulted in a
4.7-fold increase in the atherosclerotic plaque area in the
aortic root (dexamethasone treated, 0.461  0.199 mm2;
control, 0.098 0.047 mm2; P .001).
Short-term 7-day treatment with dexamethasone
reduces vein graft thickening. Because long-term treat-
ment with dexamethasone is accompanied by serious side
effects, the effect of short-term dexamethasone treatment
on vein graft thickening was assessed. Six ApoE3Leiden
mice underwent vein graft surgery and were treated for 1
week with dexamethasone, after which dexamethasone was
withdrawn and mice were allowed to drink normal drinking
water. The control group consisted of mice that underwent
vein graft surgery and were not exposed to dexamethasone.
After 4 weeks, vessel wall thickness was determined. No
difference was seen in plasma cholesterol levels and animal
weight before surgery and at the time of death (data not
shown). A reduction of vein graft thickening was seen in the
vein grafts of the dexamethasone-treated mice (0.25 
0.07 mm2): there was a decrease of 49% when compared
with the control group (0.62 0.11 mm2; P  .04; Fig 2).
The luminal area did not differ significantly between groups
(dexamethasone, 0.67  0.09 mm2; control, 0.75  0.08
mm2; P .75). Furthermore, the lesions of animals treated
for 7 days showed a morphology similar to those of the
group treated for 28 days with dexamethasone.
Effect of dexamethasone on early expression of
proatherogenic cytokines. Because short-term dexa-
methasone treatment results in reduced graft thickening in
the long-term, we hypothesized that dexamethasone might
reduce early expression of proinflammatory cytokines in the
remodeling vein grafts and thereby hamper the initiation of
the remodeling process in the vein grafts. To study this
hypothesis, mRNA analysis of both dexamethasone-treated
and control vein grafts was performed.
The effect of dexamethasone treatment on the early ex-
pression of several proinflammatory cytokines and inflamma-
tory markers was studied in vein grafts, either dexamethasone-
treated or control, harvested 24 hours after surgery. This time
frame was chosen because previous data have shown that
cytokines are rapidly upregulated (hours after surgery; data
not shown). The cytokines and inflammatory markers used in
this experiment were selected on the basis of their involvementFig 1. Dexamethasone treatment (0.15 mg · kg1 · d1 in drinking
water) reduces vein graft thickening in hypercholesterolemic
ApoE3Leiden mice after 28 days of treatment. A, Quantification of
vein graft thickening shows a reduction of 43% in the dexamethasone-
treated animals as compared with controls (n 6; *P .05), whereas
no significant changes in luminal area were observed (B). C, Repre-
sentative cross section; arrows indicate a thickened vessel wall (stain,
hematoxylin-phloxin-saffron; original magnification, 40). No dif-
ferences were seen in the cellular composition of thickened grafts in
either group, as determined by computer-assisted morphometric
analysis. D, Alpha smooth muscle actin staining representing vascularin the process of atherosclerosis or restenosis.20-25
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were significantly downregulated in vein grafts of
dexamethasone-treated animals when compared with con-
trol vein grafts. The relative expression of TNF- in the
dexamethasone group was 0.15  0.07 (P  .021), and
that of MIP-1 was 0.12  0.06 (P  .029). Another
potent proatherogenic cytokine, MCP-1, showed a mod-
est, yet not significant, downregulation in the dexametha-
sone-treated vein grafts, with a relative expression of 0.32
 0.06 (P  .25). Dexamethasone treatment also resulted
in decreased expression of TLR-4 (relative expression, 0.36
 0.05; P  .021) and its cofactor CD14 (relative expres-
sion, 0.26  0.08;  P  .043; Fig 3).
Effect of both continuous and short-term dexa-
methasone exposure on IH formation in human saphe-
nous vein cultures. To determine whether the murine in
vivo vein graft model reacts in a similar way on stimuli as it
does on clinically relevant human tissue, we used human
saphenous vein organ cultures to study the effects of dexa-
methasone exposure on the development of IH. Human
Fig 2. Effect of 7 days of dexamethasone treatment on vein
graft thickening 28 days after surgery in hypercholesterolemic
ApoE3Leiden mice. There was a significant inhibition of vein
graft thickening in the 7-day-treated animals (A) when com-
pared with controls (n  6; *P  .05). There was no significant
difference in luminal area between groups (B). n.s., Not signif-
icant; dexa, dexamethasone.saphenous vein organ cultures were exposed for either 7 or28 days to dexamethasone in the medium (0.75 mg/mL)
and compared them with untreated control segments.
Both 7 and 28 days of exposure to dexamethasone re-
sulted in a marked reduction of IH formation (Fig 4). In the
untreated control veins, the IH surface was 0.059  0.006
mm2, whereas in the segments that underwent 28 days of
exposure to dexamethasone, IH was 0.014  0.002 mm2
(P  .006). Short-term treatment by 7 days of exposure to
Fig 3. Effect of dexamethasone treatment on the early messenger
RNA (mRNA) expression of proinflammatory cytokines in injured
vessels of ApoE3Leiden mice (n  4 per group). The relative
mRNA expression in time in the dexamethasone-treated group is
depicted compared with mRNA expression the control group
(expression in the control group was defined as 1; *P .05).MCP,
Monocyte chemotactic protein; TNF, tumor necrosis factor; MIP,
macrophage inflammatory protein; TLR, toll-like receptor.
Fig 4. Effect of either short-term (D7d) or prolonged (D28d)
dexamethasone exposure (0.75 mg/mL of medium) in intimal
hyperplasia formation in human saphenous vein organ cultures
(n  12 per group). In both dexamethasone-exposed groups, a
significantly decreased amount of intimal hyperplasia was seen
when compared with the control segments (*P  .05; original
magnification, 100; dotted line indicates the border separating
media from intima). n.s., Not significant.dexamethasone resulted in decreased IH formation of 0.018
JOURNAL OF VASCULAR SURGERY
April 2006814 Schepers et al 0.002 mm2 (P  .021 when compared with untreated
vessels; P .19 when compared with 28-day-treated vessels).
DISCUSSION
This study shows that short-term anti-inflammatory ther-
apy with dexamethasone inhibits vein graft thickening in
venous bypass grafts over an extended period of time. It is well
appreciated that atherosclerosis and other forms of vascular
remodeling, such as postangioplasty neointimal formation
and vein graft disease, are inflammatory-mediated processes.
Extending this observation to the clinical situation, it is obvi-
ous that some of the commonly used anti-inflammatory
agents would deserve further investigation in this respect. One
of the most widely used anti-inflammatory agents is the group
of corticosteroids, commonly used for several diseases such as
rheumatoid arthritis, inflammatory bowel disease, organ
transplantation, and chronic obstructive pulmonary disease.
Several preclinical studies describe the effect of cortico-
steroids on postangioplasty restenosis. The effect of dexa-
methasone has often been studied in various in vitro and
animal models for postinterventional neointima forma-
tion.5,7,9,26,27 Most animal studies show a decrease in neoin-
timal formation in the dexamethasone-treated group. Even
though it is well known that corticosteroid therapy is associ-
ated with several side effects, these findings led to the initiation
of several clinical studies to asses the beneficial effect of corti-
costeroid therapy on the development of in-stent restenosis;
most of them are still ongoing. Two studies have been recently
published that describe the effect of dexamethasone-eluting
stents. Liu et al12 showed that implantation of a dexametha-
sone-coated stent is safe and feasible. Recently another clinical
study was published. Hoffmann et al10 did not observe any
beneficial effects of the dexamethasone-coated stent on the
development of restenosis. Two other studies with conflicting
results have been published about the effect of oral corticoste-
roid treatment on the development of in-stent restenosis.
Versaci et al13 reported a striking decrease in the restenosis
rate in patients with persistently high C-reactive protein levels
when they were treated with oral immunosuppressive therapy
with prednisone. The article of Lee et al11 did not describe any
beneficial effect on the restenosis rate when patients were
pretreated with a single dose of methylprednisolone.
Whereas the effect of corticosteroids on postangio-
plasty neointimal formation is being thoroughly studied,
the effect of corticosteroids on vein graft thickening is
unknown. To our knowledge, only one study has described
a beneficial effect of dexamethasone treatment on vein graft
thickening in rats.14 However, this was not a hypercholes-
terolemic model, and the thickened graft consisted mainly
of SMCs, whereas in patients the graft lesions consist of
SMCs, macrophages, and T cells. In the study described in
this article, we used hyperlipidemic ApoE3Leiden mice in a
model of vein graft disease that highly resembles the mor-
phology of human restenotic vein grafts.
In this model, we demonstrate that continuous treat-
ment with dexamethasone for 28 days causes a significant
reduction in vein graft thickening without altering the
cellular composition of the thickened vessel wall. An out-ward remodeling was seen in these vein grafts that could be
attributed to the fact that the vessel wall of the graft is
initially very thin and consists of just a few cell layers.
Hyperplasia results in vessel wall thickening, which will
principally be outwardly directed.
However, prolonged dexamethasone treatment is
known to be accompanied by serious side effects, such as an
impaired immune response, osteoporosis, and an increased
risk of atherosclerotic events (probably because of dyslipi-
demia)28,29 in humans. Moreover, although in the 28-day
period of the vein graft experiment an effective inhibition of
vein graft thickening was observed, the first signs of nega-
tive side effects were detectable in the treated mice: these
were failure to gain weight and slightly increased plasma
cholesterol levels.
To prove that the occurrence of these clinical features
was caused by dexamethasone treatment, we included an
experiment in which ApoE3Leiden mice were treated with
the same dose of dexamethasone as in the vein graft exper-
iments, but for a prolonged period of time. The response of
the animals to dexamethasone treatment highly mimicked
what is seen in patients: impaired well-being, infections
and, most strikingly, increased atherosclerosis in the aortic
root was observed.
To analyze whether the potential problem of unwanted
side effects can be avoided, we tested whether a short
treatment with dexamethasone (7 days) directly after sur-
gery was as effective as a continuous treatment. A 49%
reduction in vein graft thickening after a 7-day treatment
with dexamethasone was observed that was comparable to
the reduction after a 28-day treatment. These data indicate
that short-term dexamethasone treatment directly after
surgery has the same potential to reduce graft thickening as
a prolonged treatment.
This information is of great importance for eventual
clinical application, because limiting the duration of dexa-
methasone treatment may avoid potential side effects.
To gain further insight into the mechanism of how
short-term dexamethasone treatment can result in a long-
term reduction of vein graft thickening, we studied the
hypothesis that dexamethasone hampers vein graft thicken-
ing by inhibiting early proinflammatory cytokine expres-
sion. Indeed, significant reductions in mRNA expression of
several proinflammatory cytokines could be detected in the
dexamethasone-treated vein grafts.
Despite a reduction in expression of proinflammatory
cytokines, dexamethasone treatment did not result in de-
creased macrophage content in the thickened grafts. This is in
contrast with previous reports of Asai et al,5 who described a
reduction in macrophage content in the atherosclerotic tissue
of cholesterol-fed rabbits. A possible explanation for this dif-
ference might be the fact that dexamethasone also reduces
SMC proliferation30 and thereby keeps the balance between
macrophages and SMCs in the vein graft unchanged.
As a final experiment and to study whether our findings in
mice can be extrapolated to human tissue, we repeated the
experiments in human saphenous vein organ cultures. Like
the short-term dexamethasone treatment in murine vein
JOURNAL OF VASCULAR SURGERY
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were exposed to dexamethasone for 7 days. The fact that in
the saphenous vein organ cultures IH is mainly an SMC
proliferation–driven process underscores the effect of dexa-
methasone on SMC proliferation, as discussed previously.
In conclusion, this study demonstrated that short-term
dexamethasone treatment leads to a reduction of lesion area
both in vein grafts in mice and in human saphenous organ
cultures, thereby minimizing the risk of unwanted systemic
side effects that occur in prolonged dexamethasone treatment.
Therefore, this approach might be suitable for further explo-
ration in patients to reduce the risk of vein graft stenosis due to
IH and accelerated atherosclerosis. However, as we learned
from previous clinical trials for postinterventional restenosis,
more research is necessary to obtain more insight about the
optimal dose and treatment period.
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